Sensorion develops innovative therapies dedicated to the treatment of vestibular and cochlear pathologies. Our scientists are focused on :

Relieving acute symptoms such as vertigo and tinnitus,
Reducing impairments (loss of balance, hearing loss ...) related to permanent damage of the inner ear,
Restore, to the extent possible, the functions already impacted.
Beginning in 2015, Sensorion launched the first clinical trial (phase 1b) with SENS-111, an innovative treatment against acute vertigo. SENS-111 will initially be tested on healthy volunteers to determine pharmacokinetics and tolerability.

Two other programs are also in the final stages of preclinical testing and Sensorion continues further development through international collaborations with academic research teams and Pharma companies.

Montpellier, FR
Size (employees)
15 (est)
Sensorion is headquartered in Montpellier, FR
Report incorrect company information

Sensorion Office Locations

Sensorion has an office in Montpellier
Show all (1)
Report incorrect company information

Sensorion Financials and Metrics

Sensorion Financials

Market capitalization (31-Oct-2017)

29.2 m

Closing share price (31-Oct-2017)

Sensorion's current market capitalization is €29.2 m.
Show all financial metrics
Report incorrect company information